

Neurofibromatose Erasmus MC/ ENCORE publicaties:

- Van Der Vaart, T. *et al.* (2013) Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial. *Lancet Neurol* 12, 1076–1083
- van Minkelen, R. *et al.* (2013) A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands. *Clin Genet* DOI: 10.1111/cge.12187
- Castrén, E. *et al.* (2012) Treatment of neurodevelopmental disorders in adulthood. *J Neurosci* 32, 14074–14079
- Acosta, M.T. *et al.* (2012) The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research. *Am J Med Genet* 158, 2225–2232
- van der Vaart, T. *et al.* (2011) Motor deficits in neurofibromatosis type 1 mice: the role of the cerebellum. *Genes Brain Behav* 10, 404–409
- Krab, L.C. *et al.* (2011) Motor learning in children with neurofibromatosis type I. *Cerebellum* 10, 14–21
- Verdijk, R.M. *et al.* (2010) TP53 mutation analysis of malignant peripheral nerve sheath tumors. *J Neuropathol Exp Neurol* 69, 16–26
- Krab, L.C. *et al.* (2009) Health-related quality of life in children with neurofibromatosis type 1: contribution of demographic factors, disease-related factors, and behavior. *J Pediatr* 154, 420–5, 425.e1
- D Krab, L.C. *et al.* (2008) Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases. *Trends Genet* 24, 498–510
- enayer, E. *et al.* (2008) Spred1 is required for synaptic plasticity and hippocampus-dependent learning. *J Neurosci* 28, 14443–14449
- Cui, Y. *et al.* (2008) Neurofibromin regulation of ERK signaling modulates GABA release and learning. *Cell* 135, 549–560
- Krab, L.C. *et al.* (2008) Impact of neurofibromatosis type 1 on school performance. *J Child Neurol* 23, 1002–1010
- Krab, L.C. *et al.* (2008) Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. *JAMA* 300, 287–294
- Balgobind, B.V. *et al.* (2008) Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. *Blood* 111, 4322–4328
- van Engelen, S.J.P.M. *et al.* (2008) Quantitative differentiation between healthy and disordered brain matter in patients with neurofibromatosis type I using diffusion tensor imaging. *AJNR American journal of neuroradiology* 29, 816–822
- Oostenbrink, R. *et al.* (2007) Parental reports of health-related quality of life in young children with neurofibromatosis type 1: influence of condition specific determinants. *J Pediatr* 151, 182–6–186.e1–2
- Crossen, M.H. *et al.* (1998) Minor disease features in neurofibromatosis type 1 (NF1) and their possible value in diagnosis of NF1 in children. *J Med Genet* 35, 624–627
- Crossen, M.H. *et al.* (1998) A prospective 10 year follow up study of patients with neurofibromatosis type 1. *Arch. Dis. Child.* 78, 408–412
- Crossen, M.H. *et al.* (1997) Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. *Pediatrics* 100, 667–670
- Crossen, M.H. *et al.* (1997) Diagnostic delay in neurofibromatosis type 1. *Eur J Pediatr* 156, 482–487
- Crossen, M.H. *et al.* (1997) Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 1? *Hum Mutat* 9, 458–464

